Sage Therapeutics, Inc. Financials

Market Capitalization $576.1 Million as of July 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-1.54
Forward PE	-2.81
Price to Sales TTM	$9.05
Price to Book MRQ	$1.17
Enterprise to Revenue	1.21
Enterprise to EBITDA	-0.22

Financial Reports as of Mar. 31, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-03-31
Profit Margin	97.50%
Operating Margin	-1489.18%
Return on Assets TTM	-31.98%
Return on Equity TTM	-54.72%

Income Statement

Revenue TTM	$91,063,000
Revenue per Share TTM	$1.52
Quarterly Revenue Growth	139.90%
Gross Profit TTM	$84,296,000
EBITDA	$-507,262,016
Net Income to Common TTM	$-503,144,000
Diluted EPS TTM	$-8.39
Quarterly Earnings Growth YoY	139.89%

Balance Sheet

Total Cash MRQ	$717,012,992
Total Cash per Share MRQ	$11.91
Total Debt MRQ	$
Total Debt to Equity MRQ	0.47
Current Ratio MRQ	12.22
Book Value per Share MRQ	$11.73

Cash Flow

Operating Cash Flow TTM	$-424,735,008
Levered Free Cash Flow TTM	$-232,904,496

SAGE Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	60,182,000
Float Shares	47,625,050
Avg 10 Volume	1,715,850
Avg 30 Volume	None
Shares Short	9,310,631
Short Ratio	11.22
Short % of Shares	23.37%
% Held by Insiders	12.47%
% Held by Institutions	95.93%

Stock Price Summary

Beta	0.85
Fifty Two Week Low	$10.92
Fifty Two Week High	$59.99
Fifty Two Week Change	-269.23%
Day 50 MA	$18.69
Day 200 MA	$22.24

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date